These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 9814955)
1. Active and passive immunization against HIV type 1 infection in chimpanzees. Murthy KK; Cobb EK; Rouse SR; McClure HM; Payne JS; Salas MT; Michalek GR AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S271-6. PubMed ID: 9814955 [TBL] [Abstract][Full Text] [Related]
2. Correlates of protective immunity against HIV-1 infection in immunized chimpanzees. Murthy KK; Cobb EK; Rouse SR; Lunceford SM; Johnson DE; Galvan AR Immunol Lett; 1996 Jun; 51(1-2):121-4. PubMed ID: 8811355 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model. Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672 [TBL] [Abstract][Full Text] [Related]
4. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Forns X; Payette PJ; Ma X; Satterfield W; Eder G; Mushahwar IK; Govindarajan S; Davis HL; Emerson SU; Purcell RH; Bukh J Hepatology; 2000 Sep; 32(3):618-25. PubMed ID: 10960458 [TBL] [Abstract][Full Text] [Related]
5. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560 [TBL] [Abstract][Full Text] [Related]
6. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Mascola JR; Stiegler G; VanCott TC; Katinger H; Carpenter CB; Hanson CE; Beary H; Hayes D; Frankel SS; Birx DL; Lewis MG Nat Med; 2000 Feb; 6(2):207-10. PubMed ID: 10655111 [TBL] [Abstract][Full Text] [Related]
7. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Shibata R; Igarashi T; Haigwood N; Buckler-White A; Ogert R; Ross W; Willey R; Cho MW; Martin MA Nat Med; 1999 Feb; 5(2):204-10. PubMed ID: 9930869 [TBL] [Abstract][Full Text] [Related]
8. Rectal transmission of human immunodeficiency virus type 1 to chimpanzees. Fultz PN; Wei Q; Yue L J Infect Dis; 1999 May; 179 Suppl 3():S418-21. PubMed ID: 10099110 [TBL] [Abstract][Full Text] [Related]
9. Systemic and mucosal immunity is elicited after both intramuscular and intravaginal delivery of human immunodeficiency virus type 1 DNA plasmid vaccines to pregnant chimpanzees. Bagarazzi ML; Boyer JD; Javadian MA; Chattergoon MA; Shah AR; Cohen AD; Bennett MK; Ciccarelli RB; Ugen KE; Weiner DB J Infect Dis; 1999 Oct; 180(4):1351-5. PubMed ID: 10479171 [TBL] [Abstract][Full Text] [Related]
10. Passive immunization for the treatment and prevention of HIV infection. Karwowska S; Zolla-Pazner S Biotechnol Ther; 1991; 2(1-2):31-48. PubMed ID: 1845123 [TBL] [Abstract][Full Text] [Related]
11. [Novel vaccines against M. tuberculosis]. Okada M Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920 [TBL] [Abstract][Full Text] [Related]
13. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis. Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948 [TBL] [Abstract][Full Text] [Related]
14. Prevention of HIV infection by passive immunization with HIV immunoglobulin. Prince AM; Reesink H; Pascual D; Horowitz B; Hewlett I; Murthy KK; Cobb KE; Eichberg JW AIDS Res Hum Retroviruses; 1991 Dec; 7(12):971-3. PubMed ID: 1812946 [TBL] [Abstract][Full Text] [Related]
15. Murine models for HIV vaccination and challenge. Boberg A; Bråve A; Johansson S; Wahren B; Hinkula J; Rollman E Expert Rev Vaccines; 2008 Feb; 7(1):117-30. PubMed ID: 18251698 [TBL] [Abstract][Full Text] [Related]
16. HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Ellenberger D; Otten RA; Li B; Aidoo M; Rodriguez IV; Sariol CA; Martinez M; Monsour M; Wyatt L; Hudgens MG; Kraiselburd E; Moss B; Robinson H; Folks T; Butera S Virology; 2006 Aug; 352(1):216-25. PubMed ID: 16725169 [TBL] [Abstract][Full Text] [Related]
17. Protection from secondary human immunodeficiency virus type 1 infection in chimpanzees suggests the importance of antigenic boosting and a possible role for cytotoxic T cells. Balla-Jhagjhoorsingh SS; Mooij P; ten Haaft PJ; Bogers WM; Teeuwsen VJ; Koopman G; Heeney JL J Infect Dis; 2001 Jul; 184(2):136-43. PubMed ID: 11424009 [TBL] [Abstract][Full Text] [Related]
18. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments. Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264 [TBL] [Abstract][Full Text] [Related]
19. Passive immunization for the treatment of HIV infection. Jacobson JM Mt Sinai J Med; 1998 Jan; 65(1):22-6. PubMed ID: 9458680 [TBL] [Abstract][Full Text] [Related]
20. [The quest for an HIV vaccine]. Girard MP Bull Acad Natl Med; 2005 May; 189(5):831-44; discussion 844. PubMed ID: 16433455 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]